Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer-Reference-Cited by-同舟云学术

Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer

Author:

Kamat Ashish M.¹,Witjes J. Alfred²,Brausi Maurizio³,Soloway Mark⁴,Lamm Donald⁵,Persad Raj⁶,Buckley Roger⁷,Böhle Andreas⁸,Colombel Marc⁹,Palou Joan¹⁰

Affiliation:

1. Department of Urology, MD Anderson Cancer Center, Houston, Texas

2. Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

3. Department of Urology, AUSL Modena, Modena, Italy

4. Department of Urology, University of Miami School of Medicine, Miami, Florida

5. Department of Surgery, University of Arizona, and BCG Oncology, Phoenix, Arizona

6. Department of Urology/Surgery, Bristol Royal Infirmary & Bristol Urological Institute, Bristol, United Kingdom

7. Department of Urology, North York General Hospital, Toronto, Ontario, Canada

8. Department of Urology, HELIOS Agnes Karll Hospital, Bad Schwartau, Germany

9. Department of Urology, Claude Bernard University, Hôpital Edouard Herriot, Lyon, France

10. Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference50 articles.

4. Low-grade Ta urothelial carcinoma of the bladder;Konety,2012

5. Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS);Babjuk,2013

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献